WO2005039502A3 - Macromer-melt formulations - Google Patents

Macromer-melt formulations Download PDF

Info

Publication number
WO2005039502A3
WO2005039502A3 PCT/US2004/035346 US2004035346W WO2005039502A3 WO 2005039502 A3 WO2005039502 A3 WO 2005039502A3 US 2004035346 W US2004035346 W US 2004035346W WO 2005039502 A3 WO2005039502 A3 WO 2005039502A3
Authority
WO
WIPO (PCT)
Prior art keywords
macromer
articles
methods
melt formulations
articles made
Prior art date
Application number
PCT/US2004/035346
Other languages
French (fr)
Other versions
WO2005039502A2 (en
Inventor
Stephen C Rowe
Durga Ananvajjula
Original Assignee
Azopax Therapeutics Llc
Stephen C Rowe
Durga Ananvajjula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azopax Therapeutics Llc, Stephen C Rowe, Durga Ananvajjula filed Critical Azopax Therapeutics Llc
Priority to CA002585024A priority Critical patent/CA2585024A1/en
Publication of WO2005039502A2 publication Critical patent/WO2005039502A2/en
Publication of WO2005039502A3 publication Critical patent/WO2005039502A3/en
Priority to US11/410,269 priority patent/US20070053954A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Abstract

The invention provides methods and articles for the administration of a biologically active substance (BAS). These methods and articles provide for the controlled and sustained delivery of relatively large quantities of these substances with a low burst effect. The articles made using the method of the invention have increased percentages (w/w) of macromer, increased crosslinking density, and reduced pore size in comparison to articles made using solution methods.
PCT/US2004/035346 2003-10-24 2004-10-22 Macromer-melt formulations WO2005039502A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002585024A CA2585024A1 (en) 2003-10-24 2004-10-22 Macromer-melt formulations
US11/410,269 US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51428603P 2003-10-24 2003-10-24
US60/514,286 2003-10-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/410,269 Continuation-In-Part US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Publications (2)

Publication Number Publication Date
WO2005039502A2 WO2005039502A2 (en) 2005-05-06
WO2005039502A3 true WO2005039502A3 (en) 2005-07-28

Family

ID=34520188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035346 WO2005039502A2 (en) 2003-10-24 2004-10-22 Macromer-melt formulations

Country Status (2)

Country Link
CA (1) CA2585024A1 (en)
WO (1) WO2005039502A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580690A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
AU2008303900A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a galanin peptide as a therapeutic agent
WO2009033692A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the peptides fibrinopeptide a and pyx-i as a therapeutic agents
CN105367664B (en) * 2015-11-04 2019-09-20 成都贝爱特生物科技有限公司 Activate GLP-1 receptor and the preparation of the fusion protein of the difunctional effect of Amylin receptor and application thereof
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN108014338A (en) * 2018-01-22 2018-05-11 安徽未名生物医药有限公司 A kind of injection basiliximab freeze-dried powder and preparation method thereof
BR112021006406A2 (en) * 2018-10-02 2021-07-06 Innocore Tech Holding B V extended release human chorionic gonadotropin (hcg) dosage form
KR20220008824A (en) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 How to treat anxiety disorders, headache disorders and eating disorders with psilocybin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US20010031260A1 (en) * 1999-12-14 2001-10-18 Genentech, Inc. Treatment method
US20020049155A1 (en) * 2000-05-31 2002-04-25 Hogenkamp Henricus P.C. Cobalamin compounds useful as cardiovascular agents and as imaging agents
US20020151525A1 (en) * 2000-10-25 2002-10-17 Collins Douglas A. Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US20010031260A1 (en) * 1999-12-14 2001-10-18 Genentech, Inc. Treatment method
US20020049155A1 (en) * 2000-05-31 2002-04-25 Hogenkamp Henricus P.C. Cobalamin compounds useful as cardiovascular agents and as imaging agents
US20020151525A1 (en) * 2000-10-25 2002-10-17 Collins Douglas A. Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation

Also Published As

Publication number Publication date
WO2005039502A2 (en) 2005-05-06
CA2585024A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
MX2007002189A (en) Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery.
MX295630B (en) Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients.
WO2004098393A3 (en) Delivery system for endoluminal implant
AU2003258209A1 (en) Active agent delivery systems, medical devices, and methods
EP2279732A3 (en) Compounds and compositions for delivering active agents
WO2005048952A3 (en) Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
WO2003082247A3 (en) Drug microparticles
WO2005058537A3 (en) Medical devices and methods of making the same
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2006055603A3 (en) Injectable nanoparticulate olanzapine formulations
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2002070438A3 (en) Compositions for delivering bisphosphonates
ZA200301813B (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
AU2003273181A1 (en) Vehicles for delivery of biologically active substances
HK1087031A1 (en) Subcutaneous implants having limited initial release of the active principle and subsequent linearlyvarying extended release thereof
WO2006079928A3 (en) Polyelectrolyte multilayer film, preparation and uses thereof
WO2005009356A3 (en) Method for the preparation of controlled release formulations
WO2006030402A3 (en) Dual compartment osmotic delivery device
EP2308479A3 (en) Compounds and compositions for delivering active agents
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2003074033A8 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
AU2002254942A1 (en) Paracetamol solutions which are stable in storage and ready for infusion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11410269

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11410269

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2585024

Country of ref document: CA